Merck’s Stock Decline: Analyzing Financial Performance and Outlook

Merck & Co., Inc. (MRK), valued at a market capitalization of $226.1 billion, is a prominent healthcare company recognized for its extensive portfolio of blockbuster drugs. Among these is PD-L1 inhibitor Keytruda, known for its approval in several cancer treatments. Headquartered in Rahway, New Jersey, Merck specializes in a variety of human health pharmaceutical products, including those in oncology, immunology, neuroscience, virology, cardiovascular health, and diabetes.

Companies with a valuation of $200 billion or more are typically classified as “mega-cap” stocks, a category that Merck fits into seamlessly. As one of the largest pharmaceutical companies globally, it offers groundbreaking healthcare solutions through prescription medications, vaccines, biological therapies, and products for animal health. These innovations include therapies for cancer, diabetes medications, and crucial vaccines against HPV and chickenpox.

Active Investor: FREE newsletter going behind the headlines on the hottest stocks to uncover new trade ideas

Despite its robust portfolio, Merck’s stock has seen a decline of 32.7% from its 52-week high of $134.63, reached on June 25, 2024. Additionally, over the past three months, the stock has dropped by 12.2%, underperforming the broader S&P 500 Index ($SPX), which experienced a 2.3% decrease during the same period.

Looking at the longer perspective, Merck’s performance is further concerning. The stock has decreased by 29.8% over the past 52 weeks, significantly lagging behind SPX’s return of 15.4%. On a six-month basis, Merck shares are down nearly 22.3%, while SPX reflects a modest gain of 4.2% over the same timeframe.

Merck’s bearish trend is underscored by its trading patterns. Since late July, the stock has been trading below its 200-day moving average and has remained beneath its 50-day moving average since late June 2024.

A notable drop occurred on February 4, when Merck’s shares fell 9.1% following its Q4 earnings report. Despite surpassing earnings expectations with an adjusted earnings figure of $1.72 per share and $15.6 billion in revenue, the market response was not favorable.

Merck’s improved net income was a bright spot, rising from a mere $0.03 per share in the same quarter last year. This positive change stemmed from a one-time charge related to a collaboration with Daiichi Sankyo in the previous year. Revenue also grew by 7% year-over-year, largely driven by robust demand for Keytruda and other oncology treatments.

However, investor confidence took a hit due to Merck’s fiscal 2025 outlook, which did not meet market expectations. The company forecasts full-year revenue between $64.1 billion and $65.6 billion. This projection is negatively influenced by its decision to pause shipments of Gardasil vaccines to China, amid economic weakness and reduced consumer demand in that region.

In comparison, Merck’s rival, Bristol-Myers Squibb Company (BMY), has performed significantly better, gaining 16.4% over the past year and 22.2% over the past six months.

Despite these challenges, analysts maintain a cautiously optimistic view of Merck’s potential. The stock currently holds a “Moderate Buy” rating from 23 analysts, with a mean price target of $111.90, suggesting a potential upside of 23.5% from current levels.

On the date of publication, Neharika Jain did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information, please view the Barchart Disclosure Policy here.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.